StockData
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. (SMMT) shareholders

SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$10.50−0.17 (-1.59%)

Close on Nov 18, 2026Market cap $8.38BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
17.0%
136M of 798M shares
Institutional holders
242
58 new, 35 sold out
Net institutional buying
17M
In Q2 2026
Insider trades, 12 months
6 buys · 0 sales
Net bought $103.62M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Robert W. Duggan555,736,06075.20%13D (active) amendmentSep 11, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of SMMTValueChange% of portfolio
Baker Bros. Advisors LP32,786,3484.11%$477.70M−3,604,7152.39%
FMR LLC10,043,9471.26%$146.34M−809,2520.01%
State Street Corp9,536,7961.20%$138.95M+2,508,6360.00%
BlackRock, Inc.9,529,0411.19%$138.84M−124,7170.00%
Vanguard Capital Management LLC5,734,4840.72%$83.55M+22,6820.00%
UBS Group AG5,233,7980.66%$76.26M+1,553,4830.01%
Vanguard Portfolio Management LLC5,042,1900.63%$73.46M−191,0620.00%
Goldman Sachs Group Inc4,513,3990.57%$65.76M+4,202,6710.01%
Price T Rowe Associates Inc /Md/3,893,8200.49%$56.73M−4,384,0390.01%
Point72 Asset Management, L.P.3,697,8030.46%$53.88M+2,913,6170.06%
Geode Capital Management, LLC3,427,2630.43%$49.95M+111,4090.00%
Millennium Management LLC2,349,0810.29%$34.23M+2,222,8080.01%
Adage Capital Partners Gp, L.L.C.1,989,5910.25%$28.99MNew0.04%
Balyasny Asset Management L.P.1,904,2540.24%$27.74M+1,355,9190.03%
Citadel Advisors LLC1,725,7160.22%$25.14M+1,283,9730.00%
abrdn plc1,693,6260.21%$24.68M+1,028,2620.03%
Squarepoint Ops LLC1,590,7360.20%$23.18M+976,8590.03%
Morgan Stanley1,450,0190.18%$21.13M−200,5720.00%
Norges Bank1,382,5190.17%$20.14MNew0.00%
Logos Global Management LP1,350,0000.17%$19.67MNew0.85%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026242136M17.0%58 / 9757 / 3532M15M
Q1 2026222119M14.9%58 / 8349 / 3725M13M
Q4 2025206118M14.8%35 / 7466 / 6023M8M
Q3 2025232103M12.9%51 / 7967 / 4214M8M
Q2 202522698M12.3%67 / 6472 / 4220M21M
Q1 202520299M12.4%38 / 7369 / 3112M5M
Q4 202419693M11.6%62 / 7636 / 2613M5M
Q3 202416485M10.6%65 / 5033 / 1826M6M
Q2 202412172M9.1%40 / 1947 / 2035M14M
Q1 202410351M6.4%18 / 4028 / 1019M2M
Q4 20239533M4.2%10 / 3620 / 65M4M
Q3 20239132M4.1%8 / 3322 / 132M4M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

186 funds held SMMT in Q2 2026, 66% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of SMMTValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF7,453,1370.93%$108.59M1.01%Jun 30, 2026
Vanguard Total Stock Market Index Fund3,707,5480.46%$54.02M0.00%Jun 30, 2026
Vanguard Small-Cap Index Fund2,667,3170.33%$38.86M0.02%Jun 30, 2026
Fidelity Growth Company Fund2,652,7370.33%$46.53M0.05%May 31, 2026
T. Rowe Price Health Sciences Fund, Inc.2,531,2310.32%$36.88M0.31%Jun 30, 2026
Vanguard Extended Market Index Fund1,778,3610.22%$25.91M0.03%Jun 30, 2026
Vanguard Small-Cap Value Index Fund1,691,3820.21%$24.64M0.04%Jun 30, 2026
Select Biotechnology Portfolio1,067,6690.13%$18.73M0.36%May 31, 2026
iShares Biotechnology ETF955,9120.12%$13.93M0.15%Jun 30, 2026
Select Health Care Portfolio800,0000.10%$14.03M0.24%May 31, 2026
Fidelity Extended Market Index Fund797,5190.10%$13.99M0.03%May 31, 2026
iShares Russell Mid-Cap Growth ETF791,5470.10%$11.53M0.05%Jun 30, 2026
Fidelity Growth Company K6 Fund778,9180.10%$13.66M0.05%May 31, 2026
Fidelity Series Growth Company Fund659,2830.08%$11.56M0.05%May 31, 2026
iShares Russell Mid-Cap ETF554,6240.07%$8.08M0.01%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Mahkam ZanganehCo-Chief Executive Officer, Director, 10% owner610,515,80976.53%Nov 16, 2026
Robert W. DugganCo-Chief Executive Officer, Director, 10% owner610,515,80976.53%Nov 16, 2026
Manmeet Singh SoniCOO and CFO, Director3,224,3750.40%Nov 16, 2026
Bhaskar AnandChief Accounting Officer261,0470.03%Oct 14, 2026
Jeff HuberDirector50,0520.01%Jan 6, 2026
Mostafa RonaghiDirector––Jan 6, 2026
Kenneth A. ClarkDirector––Jan 6, 2026
Robert F. BoothDirector––Jan 6, 2026
Yu XiaDirector32,057,1474.02%Jan 6, 2026
Alessandra CesanoDirector––Jan 6, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Manmeet Singh Soni
COO and CFO, Director
Nov 16, 2026Option exercise+100,000$1.37$137.00K3,224,375
Mahkam Zanganeh
Co-Chief Executive Officer, Director, 10% owner
Nov 16, 2026Option exercise+500,000$1.06$530.00K531,000
Robert W. Duggan
Co-Chief Executive Officer, Director, 10% owner
Nov 16, 2026Option exercise+500,000$1.06$530.00K531,000
Bhaskar Anand
Chief Accounting Officer
Oct 8, 2026Award+100,000––261,047
Mahkam Zanganeh
Co-Chief Executive Officer, Director, 10% owner
Jun 12, 2026Buy+3,810,000$13.12$49.99M573,883,879
Robert W. Duggan
Co-Chief Executive Officer, Director, 10% owner
Jun 12, 2026Buy+3,810,000$13.12$49.99M573,883,879
Manmeet Singh Soni
COO and CFO, Director
Jun 4, 2026Buy+25,000$14.46$361.50K3,098,603
Manmeet Singh Soni
COO and CFO, Director
Jun 4, 2026Buy+25,000$14.43$360.75K3,123,603
Robert W. Duggan
Co-Chief Executive Officer, Director, 10% owner
Jun 4, 2026Buy+100,000$14.60$1.46M25,824,474
Mahkam Zanganeh
Co-Chief Executive Officer, Director, 10% owner
Jun 4, 2026Buy+100,000$14.60$1.46M25,824,474
Bhaskar Anand
Chief Accounting Officer
Oct 21, 2025Award+26,680$18.74$499.98K159,751
Robert W. Duggan
Co-Chief Executive Officer, Director, 10% owner
Oct 21, 2025Award+13,980,789$18.74$262.00M570,073,879
Robert W. Duggan
Co-Chief Executive Officer, Director, 10% owner
Oct 21, 2025Buy+26,680$18.74$499.98K76,680
Robert W. Duggan
Co-Chief Executive Officer, Director, 10% owner
Oct 21, 2025Award+266,808$18.74$5.00M25,724,474
Manmeet Singh Soni
COO and CFO, Director
Oct 21, 2025Award+53,361$18.74$999.99K3,073,603
Yu Xia
Director
Oct 21, 2025Buy+533,617$18.74$10.00M32,057,147
Mahkam Zanganeh
Co-Chief Executive Officer, Director, 10% owner
Oct 21, 2025Award+13,980,789$18.74$262.00M570,073,879
Mahkam Zanganeh
Co-Chief Executive Officer, Director, 10% owner
Oct 21, 2025Buy+26,680$18.74$499.98K76,680
Mahkam Zanganeh
Co-Chief Executive Officer, Director, 10% owner
Oct 21, 2025Award+266,808$18.74$5.00M25,724,474
Robert W. Duggan
Co-Chief Executive Officer, Director, 10% owner
Sep 11, 2025Buy+5,000$18.07$90.35K556,093,090
Mahkam Zanganeh
Co-Chief Executive Officer, Director, 10% owner
Sep 11, 2025Buy+5,000$18.07$90.35K556,093,090
Robert W. Duggan
Co-Chief Executive Officer, Director, 10% owner
Sep 10, 2025Buy+333,394$17.68$5.89M556,088,090
Mahkam Zanganeh
Co-Chief Executive Officer, Director, 10% owner
Sep 10, 2025Buy+333,394$17.68$5.89M556,088,090
Mahkam Zanganeh
Co-Chief Executive Officer, Director, 10% owner
May 30, 2025Option exercise+74,545$2.64$196.80K555,754,696
Robert W. Duggan
Co-Chief Executive Officer, Director, 10% owner
May 30, 2025Option exercise+74,545$2.64$196.80K555,754,696
Robert W. Duggan
Co-Chief Executive Officer, Director, 10% owner
Apr 8, 2025Option exercise+3,985,055$1.58$6.30M555,680,151
Mahkam Zanganeh
Co-Chief Executive Officer, Director, 10% owner
Apr 8, 2025Option exercise+3,985,055$1.58$6.30M555,680,151
Mahkam Zanganeh
Co-Chief Executive Officer, Director
Oct 3, 2024Option exercise+315,681$1.58$498.78K10,199,776
Robert W. Duggan
Co-Chief Executive Officer, Director, 10% owner
Sep 11, 2024Award+3,325,991$22.70$75.50M551,695,096
Bhaskar Anand
Chief Accounting Officer
Sep 11, 2024Award+22,026$22.70$499.99K131,426
Mahkam Zanganeh
Co-Chief Executive Officer, Director
Sep 11, 2024Award+44,052$22.70$999.98K24,967,852
Jeff Huber
Director
Sep 11, 2024Award+44,052$22.70$999.98K44,052
Manmeet Singh Soni
COO and CFO, Director
Sep 11, 2024Award+44,052$22.70$999.98K3,020,242
Mahkam Zanganeh
Chief Executive Officer, Director
Mar 27, 2024Buy+26,000$3.72$96.72K520,814
Mahkam Zanganeh
Chief Executive Officer, Director
Mar 27, 2024Buy+34,321$3.72$127.67K24,923,800
Mahkam Zanganeh
Chief Executive Officer, Director
Mar 27, 2024Buy+20,000$3.71$74.20K50,000
Mahkam Zanganeh
Chief Executive Officer, Director
Mar 26, 2024Buy+30,000$3.75$112.50K30,000
Ankur Dhingra
Chief Financial Officer
Mar 26, 2024Buy+100,000$3.75$375.00K354,958
Ankur Dhingra
Chief Financial Officer
Dec 13, 2023Buy+19,700$2.17$42.75K254,958
Ankur Dhingra
Chief Financial Officer
Dec 13, 2023Buy+700$2.15$1.51K235,258
Mahkam Zanganeh
Chief Executive Officer, Director
Dec 12, 2023Buy+5,000$2.07$10.35K494,814
Mahkam Zanganeh
Chief Executive Officer, Director
Dec 11, 2023Option exercise+489,814$1.44$705.33K489,814
Mahkam Zanganeh
Chief Executive Officer, Director
Dec 11, 2023Option exercise+315,681$1.58$498.78K24,889,479
Manmeet Singh Soni
Chief Operating Officer, Director
Oct 13, 2023Buy+2,976,190$1.68$5.00M2,976,190
Mahkam Zanganeh
Co-CEO & President, Director
Mar 8, 2023Buy+6,748,629$1.05$7.09M9,884,095
Mahkam Zanganeh
Co-CEO & President, Director
Mar 8, 2023Buy+16,778,415$1.05$17.62M24,573,798
Mahkam Zanganeh
Co-Chief Executive Officer, Director
Mar 8, 2023Buy+804,672$1.05$844.91K1,178,529
Mahkam Zanganeh
Co-Chief Executive Officer, Director
Mar 8, 2023Buy+6,748,629$1.05$7.09M9,884,095
Mahkam Zanganeh
Co-Chief Executive Officer, Director
Mar 8, 2023Buy+15,973,743$1.05$16.77M23,395,269
Yu Xia
Director
Mar 7, 2023Buy+21,523,530$1.05$22.60M21,523,530
Ankur Dhingra
Chief Financial Officer
Mar 7, 2023Buy+196,362$1.05$206.18K234,558
Robert W. Duggan
Chief Executive Officer, Director
Mar 6, 2023Buy+376,489,880$1.05$395.31M552,354,161
Yu Xia
Director
Jan 17, 2023Buy+10,000,000$2.51$25.10M10,000,000
Mahkam Zanganeh
Co-CEO & President, Director
Dec 6, 2022Other+373,857––10,930,849
Robert W. Duggan
Chief Executive Officer, Director
Dec 6, 2022Other+9,346,434––171,879,226
Ankur Dhingra
Chief Financial Officer
Aug 16, 2022Buy+13,027$0.97$12.64K39,527
Ankur Dhingra
Chief Financial Officer
Aug 16, 2022Buy+24,658$0.97$23.92K38,196
Robert W. Duggan
Chief Executive Officer, Director
Aug 16, 2022Buy+94,849,203$0.97$92.00M162,532,792
Mahkam Zanganeh
Co-CEO & President, Director
Aug 16, 2022Buy+1,030,925$0.97$1,000.00K3,135,466
Mahkam Zanganeh
Co-CEO & President, Director
Aug 16, 2022Buy+184,430$0.97$178.90K359,969

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
5.30%
42M shares short
Days to cover
9.4
At 4M shares a day
Change since last report
+3.3%
From 41M shares
Short volume, 20 days
50.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Summit Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,094,668 shares on Sep 21, 2026 over the last 90 days.

See a number that looks wrong?